![Kelly Chow](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Benjamin Cravatt | M | 54 |
Belharra Therapeutics, Inc.
![]() Belharra Therapeutics, Inc. Medical/Nursing ServicesHealth Services Belharra Therapeutics, Inc. is a drug discovery company that utilizes a unique photoaffinity-based chemoproteomics platform to identify novel small molecule drug candidates for previously difficult-to-treat diseases and conditions. The company is based in San Diego, CA, with its primary lab and offices located in the area. Belharra's proprietary discovery engine allows for the identification of small molecule starting points for drug development on any protein, in any conformational state, and in any cell type. The company was founded in 2021 by John Teijaro, Christopher G. Parker, Stuart L. Schreiber, and Benjamin F. Cravatt, and has since been led by CEO Jeffrey Jonker. | 3 ans |
Jeffrey Jonker | M | 51 |
Belharra Therapeutics, Inc.
![]() Belharra Therapeutics, Inc. Medical/Nursing ServicesHealth Services Belharra Therapeutics, Inc. is a drug discovery company that utilizes a unique photoaffinity-based chemoproteomics platform to identify novel small molecule drug candidates for previously difficult-to-treat diseases and conditions. The company is based in San Diego, CA, with its primary lab and offices located in the area. Belharra's proprietary discovery engine allows for the identification of small molecule starting points for drug development on any protein, in any conformational state, and in any cell type. The company was founded in 2021 by John Teijaro, Christopher G. Parker, Stuart L. Schreiber, and Benjamin F. Cravatt, and has since been led by CEO Jeffrey Jonker. | 3 ans |
Tom Woiwode | M | - |
Belharra Therapeutics, Inc.
![]() Belharra Therapeutics, Inc. Medical/Nursing ServicesHealth Services Belharra Therapeutics, Inc. is a drug discovery company that utilizes a unique photoaffinity-based chemoproteomics platform to identify novel small molecule drug candidates for previously difficult-to-treat diseases and conditions. The company is based in San Diego, CA, with its primary lab and offices located in the area. Belharra's proprietary discovery engine allows for the identification of small molecule starting points for drug development on any protein, in any conformational state, and in any cell type. The company was founded in 2021 by John Teijaro, Christopher G. Parker, Stuart L. Schreiber, and Benjamin F. Cravatt, and has since been led by CEO Jeffrey Jonker. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Jeremy S. Caldwell | M | 55 |
Belharra Therapeutics, Inc.
![]() Belharra Therapeutics, Inc. Medical/Nursing ServicesHealth Services Belharra Therapeutics, Inc. is a drug discovery company that utilizes a unique photoaffinity-based chemoproteomics platform to identify novel small molecule drug candidates for previously difficult-to-treat diseases and conditions. The company is based in San Diego, CA, with its primary lab and offices located in the area. Belharra's proprietary discovery engine allows for the identification of small molecule starting points for drug development on any protein, in any conformational state, and in any cell type. The company was founded in 2021 by John Teijaro, Christopher G. Parker, Stuart L. Schreiber, and Benjamin F. Cravatt, and has since been led by CEO Jeffrey Jonker. | 2 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 4 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Kelly Chow
- Réseau Personnel